Crossmark

The prevalence of overtreatment of osteoporosis: results from the PAADRN trial

Crossref DOI link: https://doi.org/10.1007/s11657-018-0517-6

Published Online: 2018-09-28

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hall, Sylvie F. http://orcid.org/0000-0002-1690-9898
Wright, Nicole C.

Wolinsky, Fredric D.

Lou, Yiyue

Edmonds, Stephanie

Roblin, Douglas

Jones, Michael

Saag, Kenneth

Cram, Peter
License Information

Text and Data Mining valid from 2018-09-28
More Information

Article History

Received: 6 September 2018

Accepted: 16 September 2018

First Online: 28 September 2018

Compliance with ethical standards

:

: Cram, Jones, Lou, and Wolinsky had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

: P Cram, M Jones, F Wolinsky, S Edmonds, S Hall, Y Lou, and D. Roblin have no conflicts of interest. NC Wright has received unrestricted grant support from Amgen for work unrelated to this project, and is a consultant to Pfizer. KG Saag has received grants from Amgen, Eli Lilly, and Merck and has served as a paid consultant to Amgen, Eli Lilly, and Merck.